AstraZeneca divests Seroquel rights: US and Canada
3 December 2019 07:00 GMT AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada Sale to Cheplapharm supports AstraZeneca's focus on main therapy areas AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada. Ruud Dobber,